AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03865732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganaxolone
Description: active drug
Study NCT03865732 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: inactive
Study NCT01286311 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Direct-to-patient tailored cardiovascular risk message system
Description: Patient informational mailings
Study NCT05583656 — intervention group
Intervention type: PROCEDURE
Intervention: Pulmonary valve replacement
Description: Surgical replacement of the pulmonary valve using the Edwards Inspiris Resilia prosthesis.
Study NCT01853384 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HP802-247
Description: Study Dosage / Usage: 260 µL (130 µL, one spray, of each solution) containing 0.5 X 10(6th) cells per mL every 14 days.
Study NCT01853384 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: HP802-247 Vehicle
Description: HP802-247 Vehicle consists of two separate components, a fibrinogen solution (Component 1) and a cell free thrombin solution which is identical to Component 2 except that no keratinocytes and no fibroblasts are present. A single dose is created when combined on the wound surface.
Study NCT04595513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAVT-18 (sirolimus)
Description: The investigational drug product to be used in this study is TAVT-18, a proprietary formulation of sirolimus in clinical development, by Tavanta Therapeutics, Inc. It is provided in a powder formulation in pre-measured vials.
Study NCT04428996 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Cognition and Interaction Training (SCIT)
Description: The social cognition and interaction training (SCIT) is a manual-guide group intervention that can apply to people with serious mental illness. There have been evidences showing that the SCIT could improve emotional perception, theory of mind, attribution bias, and social relationship.
Study NCT03210324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone tablets
Description: Daily 10mg, Po, Qd, each 10mg/tablets。Start from 1 to 3 days of the menstruation, take 1 tablet after 2 hours of fasting, and no eating for 2 hours after taking the pill. Group A and group B: treatment for 12 weeks, Group C: treatment for 24 weeks.
Study NCT04097509 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AFG application on palatinal wound healing
Description: 9 ml venous blood collected from the patient was transferred to the tube without any anticoagulants. In the protocol, venous blood collected in the tube was centrifuged for 2 minutes at 2700 rpm (approximately 692 g) in a special centrifuge (Medifuge, Silfradent, Italy) to obtain two layers: the lower layer of red blood cells and the upper layer of AFG. The AFG at the top of the tube was collected by means of an injector and transferred to the metal godet. It was held for 15-20 minutes for polymerization. After polymerization occurred, the polymerized AFG in the metal gum was applied to the wound surface in the donor site . No suture or tissue glue was used. Adhesive properties of AFG were utilized.
Study NCT04097509 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: i-PRF application on palatinal wound healing
Description: 10 ml venous blood collected from the patient was transferred to the tube without any anticoagulants. Based on G force, collected venous blood were centrifuged at 2300 rpm (about 241 g) in a centrifuge (PC-O2, Process for PRF, Nice, France) for 3 minutes to obtain two layers: The two layers are the lower layer of red blood cells and the upper layer of i-PRF. The i-PRF at the top of the tube was collected with a syringe and transferred to the metal godet. It was held for 20-25 minutes for polymerization. After the polymerization, the polymerized i-PRF was applied to the wound surface in the donor site. No suture or tissue glue was used. Adhesive properties of AFG were utilized.
Study NCT04097509 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: no application
Study NCT02586467 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gain-Framed
Description: Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Gain-Framed message condition will receive message content that highlights the potential benefits of consuming milk and milk products (i.e., high protein content, stronger hair and nail etc.)
Study NCT02586467 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loss-Framed
Description: Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Loss-Framed message condition will receive message content that highlights the potential losses of not consuming milk and milk products (i.e., lack of essential nutrients, less calcium).
Study NCT02586467 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Regulatory Efficacy
Description: Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Self-Regulatory Efficacy message condition will receive information pertaining to how to include milk and milk products within their diet. This information will come in the form of recipes, meal planning, food combining etc.
Study NCT02586467 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gain-Framed + Self-Regulatory Efficacy
Description: Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Gain-Framed message + Self-Regulatory Efficacy condition will receive message content that highlights the potential benefits of consuming milk and milk products (i.e., high protein content, stronger hair and nail etc.) and information pertaining to how to include milk and milk products within their diet.
Study NCT02586467 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loss-Framed + Self-Regulatory Efficacy
Description: Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Loss-Framed message + Self-Regulatory Efficacy condition will receive message content that highlights the potential losses of not consuming milk and milk products (i.e., lack of essential nutrients, less calcium) and information pertaining to how to include milk and milk products within their diet.
Study NCT00905294 — intervention group
Intervention type: OTHER
Intervention: Blood draws
Description: Observational: blood draws only
Study NCT01705366 — intervention group
Intervention type: PROCEDURE
Intervention: Non-MAKO® Robot Assisted Total Knee Arthroplasty
Description: Patients undergoing a non-MAKO® robot assisted surgery to replace one or more compartments of the knee.
Study NCT01705366 — intervention group
Intervention type: PROCEDURE
Intervention: MAKO® Robot Assisted Medial Knee Arthroplasty
Description: Patients undergoing a MAKO® robot assisted surgery to replace the medial compartment of the knee.
Study NCT01705366 — intervention group
Intervention type: PROCEDURE
Intervention: MAKO® Robot Assisted Medial and PF Knee Arthroplasty
Description: Patients undergoing a MAKO® robot assisted surgery to replace the medial and patellofemoral (PF) compartments of the knee
Study NCT01705366 — intervention group
Intervention type: DEVICE
Intervention: RESTORIS Multicompartmental Knee System
Description: The RESTORIS Multicompartmental Knee (MCK) System components are intended for single or multicompartmental knee replacement used in conjunction with the MAKO® Robotic Arm Interactive Orthopedic System (RIO®). The components can be used for medial compartment, lateral compartment, patellofemoral compartment, or bicompartmental (medial and patellofemoral compartments) knee replacement. The device is intended to be used with bone cement.
Study NCT01705366 — intervention group
Intervention type: DEVICE
Intervention: Depuy Knee Replacement System
Description: The Depuy Knee Replacement System components are intended for use in total knee replacement. These components are intended for implantation with bone cement.
Study NCT01705366 — intervention group
Intervention type: DEVICE
Intervention: Stryker® Knee Replacement System
Description: The Stryker® Knee Replacement System components are intended for use in total knee replacement. These components are intended for implantation with bone cement.
Study NCT03755115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin plus SHR1210
Description: First intravenous injection of epirubicin injection, D1,30mg/m\^2 Then intravenous administration with SHR-1210,D1, a fixed dose of 200mg, 30min per infusion, Q2W. The total dose of epirubicin is 360 mg/m\^2.next SHR-1210 single drug maintenance .Until to secdonary disease progression or intolerance side effects.Evaluate efficacy every 3 cycles.
Study NCT01299285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3009104
Description: Administered orally
Study NCT02027584 — intervention group
Intervention type: OTHER
Intervention: collection of remnant of clinically indicated blood sample
Description: collection of remnant of clinically indicated blood sample
Study NCT04179526 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdiagnostic Internet-delivered REBT
Description: The protocol is based on Rational Emotive and Behavioral Therapy (REBT; Ellis, 1962, 1994). The program will consist of 8 modules, delivered online over six weeks.
Study NCT03903978 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: The training protocol consists of 6 weekly modules:~0.Welcome:Introduction module to the program, with an explanation about the tools and the way to use CORE~1. Psychoeducation: Explanation of psychological wellbeing and the concept of resilience~2. Autonomy, building my way: Enhancement of autonomy~3. Mindfulness and self-compassion:Training in mindfulness, savoring, and an attitude of self-compassion~4. Overcoming obstacles: Development of coping strategies to deal with daily difficulties in life~5. Connecting to others:Acknowledge the relevance of relationships and how they can be helpful in the construction of well-being~6. Purpose in life and personal growth:Approach the future with a positive attitude, planning goals for the future.
Study NCT03903978 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy lifestyle
Description: 1. Beginning of a lifestyle change The patient will learn to identify healthy and risky behaviors and recognize obstacles that prevent them from adopting a healthy lifestyle.~2. Physical activity The importance of moving on and activating behavior will be taught through regular exercise information to improve mood.~3. Diet This module is dedicated to teaching the importance of diet for good physical and mental health. The Mediterranean diet will be taken as an example for a balanced and balanced diet, because it does not differ from the habits of other countries.~4. Sleep The importance of good sleep will be addressed with information and strategies for understanding the relationship between sleep and overall health.
Study NCT00486954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: 6 pills at 250 mg each once daily
Study NCT00486954 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Infusion at 80 mg/m2 weekly
Study NCT00486954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Infusion at 80 mg/m2 weekly
Study NCT01255800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-926 and Cetuximab
Description: * Patients will receive Cetuximab IV every week.~* Starting on Day 15 of the first cycle, Patients will take IPI-926by mouth every day.
Study NCT01482325 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood pressure monitoring with GE Healthcare DASH2500 Patient Monitor
Description: 10-20 Non-Invasive Blood Pressure readings on investigational software in the DASH2500 Patient Monitor
Study NCT01751295 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin, pre-treatment 80 mg/day for 4 days before PCI
Study NCT02983721 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transradial
Description: transradial route for coronary angiography and PCI
Study NCT02983721 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transfemoral
Description: transfemoral route for coronary angiography and PCI
Study NCT00286026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: 1 gm Azithromycin orally, provided as four 250 mg tablets for adults; pediatric suspension will be provided to children > 1 year old (20 mg/kg body weight) to a maximal dose of 500 mg. One dose vs 2 doses given 30 days apart.
Study NCT00768755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: axitinib
Description: 5mg BID po up to max 10mg BID po
Study NCT00768755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: axitinib
Description: 5mg BID po up to max 10mg BID po paused for 3 days before each cycle of concomitant chemotherapy
Study NCT00768755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy
Description: Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles
Study NCT00768755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: axitinib
Description: 5mg BID po up to max 10mg BID po paused before each concomitant chemotherapy
Study NCT01967394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of internet based social marketing intervention
Description: Eleven counties in Kentucky will be targeted with ads on Google and Facebook that direct adolescent mothers to an Internet-based social marketing intervention. The ads will be implemented using Facebook's and Google's ad network. The ads are setup, configured, and adjusted online. Facebook has identified key words that are recommended for adolescent mothers: 16 and pregnant, teen mom,' and names of television shows with subject matter specific to adolescent mothers. We will target the ads to correspond to a geographical area that specifies a distance from the largest city in each county, and we will specify county lines. Ads will only appear on the Internet in the counties that are targeted for the intervention.
Study NCT01967394 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No use of social media
Description: No social media ads will be available in these counties.
Study NCT02323945 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AIH
Description: Participants will breathe intermittent low oxygen via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of fraction of inspired oxygen (FiO2) = 0.10±0.02 (hypoxia). Participants will receive treatment on 5 consecutive days.
Study NCT02323945 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Walk
Description: 30 minutes of walking practice consisting of 5 repetitions of 6-minute walks
Study NCT02323945 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strength
Description: 30 minutes of isometric ankle plantar flexion torque practice broken into 3 sets of 10 repetitions
Study NCT02050815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162
Study NCT00670488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2206
Description: MK-2206 administered as an oral formulation in rising dose levels on a QOD schedule (30 mg, 60 mg, 75 mg, and 90 mg) or QW schedule (90 mg, 135 mg, 200 mg, 250 mg, and 300 mg) in repeating 4 week cycles, depending upon allocation.
Study NCT00780793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: progressive spacing of TNF-blocker injections
Description: Experimental arm~Progressive spacing of TNF-blocker injections according to the following algorithm :~* if DAS28 ≤ 2.6 at trimestrial assessment: go for step N+1~* if DAS28 > 2.6 and DAS28 change ≤ 0.6: continue at step N~* if DAS28 > 2.6 and DAS28 change > 0.6 : return to step N-1 (relapse as defined by the European expert consensus).~Step 0 (inclusion) :~* Adalimumab 40 mg / 14 days~* Etanercept 50 mg / 7 days~Step 1 :~* Adalimumab 40 mg / 21 days~* Etanercept 50 mg / 10 days~Step 2 :~* Adalimumab 40 mg / 28 days~* Etanercept 50 mg / 14 days~Step 3 :~* Adalimumab 40 mg / 42 days~* Etanercept 50 mg / 21 days~Step 4 :~* TNF-blocker stop
Study NCT00780793 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DMARD maintenance
Description: DMARD maintenance
Study NCT00851513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: local anesthetics
Study NCT00851513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: local anesthetics
Study NCT00851513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depmedrol
Description: local steroids
Study NCT00851513 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiological serum
Description: important volumes of physiological serum
Study NCT03142932 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Individualized carbon monoxide (iCO) monitor
Description: a personal monitor for a breath test for carbon monoxide (CO)
Study NCT03142932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COach2Quit smartphone application
Description: This smartphone application works in conjunction with the iCO monitor
Study NCT03142932 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cessation counseling
Description: The advice to quit smoking message will follow NCI's 5 A's model for smoking cessation counseling. This is a simple smoking cessation counseling strategy with 5 discrete components: (1) Ask about smoking at every opportunity; (2) Advise the patient to quit smoking; (3) Assess readiness to quit; (4) Assist the patient in quitting; and (5) Arrange follow-up.
Study NCT03142932 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cessation counseling
Description: The advice to quit smoking message will follow NCI's 5 A's model for smoking cessation counseling. This is a simple smoking cessation counseling strategy with 5 discrete components: (1) Ask about smoking at every opportunity; (2) Advise the patient to quit smoking; (3) Assess readiness to quit; (4) Assist the patient in quitting; and (5) Arrange follow-up.
Study NCT01750788 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism. Decision regarding dose and duration of treatment made at the discretion of the attending investigator.
Study NCT01305044 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi Chih
Description: Tai Chi Chih (TCC), a westernized and manualized form of the ancient TC Chuan, consists of a series of 20 simple, repetitive, non-strenuous movements that involve no physical contact and emphasize a soft, flowing continuity of motion. This form of meditation through movement consists of a standardized protocol that emphasizes slow, fluid, continuous forms that integrate mental concentration, awareness, balance, shifting of body weight, gentle movement, imagery, muscle relaxation and breathing control. TCC was developed for use with elderly persons.
Study NCT00643409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azithromycin SR (Zithromax; compound: CP-62,993)
Description: Azithromycin SR 2.0 g by mouth in the form of a slurry x 1 dose
Study NCT00643409 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo
Study NCT00643409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levofloxacin
Description: levofloxacin 500 mg capsule by mouth qd x 10 days
Study NCT02007070 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous infusion
Study NCT04237792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: dexmedetomidine low, middle and high doses are provided as an intravenous bolus loading dose followed by an intravenous maintenance dose infusion throughout the MRI scan
Study NCT03467113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX008 0.2 to 0.8 mg/kg/day
Description: ZX008 drug is an oral aqueous solution of fenfluramine hydrochloride. The product is sugar free.
Study NCT03467113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Cannabidiol
Study NCT04237792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: propofol IV administration will be given if needed to maintain sedation
Study NCT02520336 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder
Study NCT02330900 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Study group
Description: Exposure to cell phone interference of the ICD
Study NCT00114452 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Provacel
Description: ex vivo cultured adult mesenchymal stem cells
Study NCT00114452 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03070548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: 1 mg of talazoparib containing100 μCi of 14C-radiolabeled talazoparib
Study NCT03108430 — intervention group
Intervention type: OTHER
Intervention: Risk factors and incidence of IP after inhalation
Description: Calculate the annual incidence of PI, the incidence of PI in inhaled patients (in each subgroup), and analyze the risk factors by logistic regression, based on the number of patients hospitalized during the study period.